Login to Your Account

Other News To Note

Thursday, June 2, 2011
Repligen Corp. completed a pre-new drug application (NDA) meeting with the FDA for its imaging product, RG1068. The Waltham, Mass.-based company is developing RG1068, a synthetic form of human secretin that stimulates the pancreatic ducts to fill with water, for magnetic resonance imaging of the pancreas. The outcome of the meeting was that Repligen will submit its NDA as previously planned.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription